Clinical experience with vincaleukoblastine sulfate in the treatment of 11 patients with Hodgkin's disease.
Eleven patients with established Hodgkin's disease were treated with vinblastine sulfate. Each patient received from 0.15 to 0.20 mg./kg. of body weight intravenously in 10 divided doses over a five-hour period as initial therapy. All had received one or more of the more established forms of treatment before being given vinblastine. The response to treatment with vinblastine was excellent in three patients, good in one, and poor in three; there was no response in four. The longest remission was 15 months. Two of the patients were father and son. The side effects of treatment in this series included alopecia, leukopenia, and septicemia.
D000328:Adult; D000368:Aged; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D014747:Vinblastine / Q000627:therapeutic use*
D014747:Vinblastine
Can Med Assoc J. 1961 Sep 2;85:579-83
13783267
Can Med Assoc J. 1961 Sep 2;85:584-91
13784890
Cancer Res. 1961 Dec;21:1542-4
13876510
Ann Intern Med. 1962 Jun;56:854-9
13895554
Cancer Res. 1960 Aug;20:1032-40
13842983
Cancer Res. 1960 Aug;20:1041-9
14402218
Ann N Y Acad Sci. 1958 Dec 5;76(3):882-94
13627916